Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia
Our PK/PD model predicted that attaining optimal PK/PD target with CI meropenem may grant prompt and intense C-RP decrease among critically ill patients receiving targeted monotherapy for Gram-negative HAP/VAP, thus anticipating efficacy.
Authors
- Matteo Rinaldi (ORCID: https://orcid.org/0000-0002-3568-5973)
- Carla Troisi (ORCID: https://orcid.org/0000-0002-9844-4472)
- Tommaso Tonetti (ORCID: https://orcid.org/0000-0001-9676-3595)
- Pierluigi Viale (ORCID: https://orcid.org/0000-0003-1264-0008)
- Antonio Daniele Pinna
- J. G. Coen van Hasselt (ORCID: https://orcid.org/0000-0002-1664-7314)
- Pier Giorgio Cojutti (ORCID: https://orcid.org/0000-0001-7135-4410)
- Federico Pea (ORCID: https://orcid.org/0000-0002-6966-7167)
Institutions
- Leiden University (NL)
- Azienda USL di Bologna (IT)
- Centre for Human Drug Research (NL)
- University of Bologna (IT)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s40262-024-01436-6
- Citations
- 1
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- European Commission
- HORIZON EUROPE Reforming and enhancing the European Research and Innovation system